Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | FDPS | P14324 | 16/20 | 0.37 |
| ▸ | BBOX1 | O75936 | 2/20 | 0.36 |
| ▸ | GGPS1 | O95749 | 7/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.32 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | PGK1 | P00558 | 1/20 | 0.31 |
| ▸ | PGK2 | P07205 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL737339 | 0.80 | FDPS (0.40) | LMNAFDPSBBOX1GGPS1PDE3A | |
| SCHEMBL483640 | 0.79 | FDPS (0.48) | LMNAFDPSBBOX1GGPS1PDE3A | |
| SCHEMBL23038652 | 0.77 | LMNA (0.43) | LMNAFDPSBBOX1GGPS1PDE3A | |
| SCHEMBL2553124 | 0.75 | PGK1 (0.39) | LMNAFDPSBBOX1GGPS1PGK1 | |
| SCHEMBL15778355 | 0.75 | LMNA (0.36) | LMNAFDPSBBOX1GGPS1PDE3A | |
| SCHEMBL192295 | 0.73 | FDPS (0.38) | LMNAFDPSBBOX1GGPS1PGK1 | |
| SCHEMBL1692406 | 0.72 | FDPS (0.52) | FDPSGGPS1PDE3A | |
| SCHEMBL23001100 | 0.72 | FDPS (0.45) | FDPSBBOX1GGPS1 | |
| SCHEMBL23001089 | 0.72 | FDPS (0.45) | FDPSBBOX1GGPS1 | |
| Hydrochloric Acid SCHEMBL17143219 | 0.72 | FDPS (0.37) | LMNAFDPSBBOX1GGPS1PGK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070077283-A1 | METHOD OF ENHANCING TRANSMUCOSAL DELIVERY OF THERAPEUTIC COMPOUNDS | NASTECH PHARMACEUTICAL COMPANY INC. | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070077283-A1 | METHOD OF ENHANCING TRANSMUCOSAL DELIVERY OF THERAPEUTIC COMPOUNDS | PGF, PLAT, PTAFR | LMNA 2169/4885FDPS 1623/4885BBOX1 2693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.